Cover Image

Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors

Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern...

Full description

Saved in:
Bibliographic Details
Main Authors: Rheinheimer, Stephan (Author) , Heußel, Claus Peter (Author) , Mayer, Philipp (Author) , Bozorgmehr, Farastuk (Author) , Winter, Hauke (Author) , Herth, Felix (Author) , Muley, Thomas (Author) , Liersch, Stephan (Author) , Bischoff, Helge (Author) , Kriegsmann, Mark (Author) , El-Shafie, Rami (Author) , Stenzinger, Albrecht (Author) , Thomas, Michael (Author) , Kauczor, Hans-Ulrich (Author) , Christopoulos, Petros (Author)
Format: Article (Journal)
Language:English
Published: 23 April 2020
In: Cancers
Year: 2020, Volume: 12, Issue: 4, Pages: 1-13
ISSN:2072-6694
DOI:10.3390/cancers12041046
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers12041046
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/12/4/1046
Get full text
Author Notes:Stephan Rheinheimer, Claus-Peter Heussel, Philipp Mayer, Lena Gaissmaier, Farastuk Bozorgmehr, Hauke Winter, Felix J. Herth, Thomas Muley, Stephan Liersch, Helge Bischoff, Mark Kriegsmann, Rami A. El Shafie, Albrecht Stenzinger, Michael Thomas, Hans-Ulrich Kauczor and Petros Christopoulos
Description
Summary:Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern under PD-1/PD-L1 inhibitors (n = 297) or chemoimmunotherapy (n = 75). Under IO monotherapy, OPD was more frequent (20% vs. 10%, p < 0.05), occurred later (median 11 vs. 5 months, p < 0.01), affected fewer sites (mean 1.1 vs. 1.5, p < 0.05), and involved fewer lesions (1.4 vs. 2.3, p < 0.05) in the first compared to later lines. Lymph nodes (42%, mainly mediastinal) and the brain (39%) were mostly affected, followed by the lung (24%) and other organs. Compared to multifocal progression, OPD occurred later (11 vs. 4 months, p < 0.001) and was associated with longer survival (26 vs. 13 months, p < 0.001) and higher tumor PD-L1 expression (p < 0.001). Chemoimmunotherapy showed a similar incidence of OPD as IO monotherapy (13% vs. 11% at 2 years). Local treatments were applied regularly for brain but only in 50% for extracranial lesions. Thus, NSCLC oligoprogression is less common under IO than under TKI, but also favorable. Since its frequency drops later in the disease, regular restaging and multidisciplinary evaluation are essential in order to exploit the full therapeutic potential.
Item Description:Gesehen am 17.07.2020
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers12041046

Similar Items